Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
International Journal of Radiation Oncology, Biology, Physics ; 114(3):e610-e611, 2022.
Article in English | Academic Search Complete | ID: covidwho-2036128

ABSTRACT

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer with an incidence of 1 million cases per year in the US. While the surgical cure rate for CSCC is >95%, some patients have high risk of recurrence as assessed by immune status, primary disease stage, extent of nodal involvement, presence of extracapsular extension, and prior treatment. Postoperative radiation therapy (RT) is recommended for these patients, but relapse with locoregional recurrence or distant metastases may still occur. C-POST is evaluating the efficacy of cemiplimab as adjuvant therapy for patients with high-risk CSCC. Here, we provide a summary of the most recent study protocol amendment. C-POST is a randomized, placebo-controlled, double-blind, multicenter Phase 3 study to evaluate cemiplimab as adjuvant treatment for patients with high-risk CSCC, based on surgical and clinicopathologic findings, who completed surgery and postoperative RT (minimum total dose 50 Gy, within 10 weeks before randomization) (NCT03969004). Patients with at least one of the following high-risk features are eligible: (1) nodal disease with (a) extracapsular extension and at least one node ≥20 mm or (b) at least three lymph nodes positive on surgical pathology report, regardless of extracapsular extension;(2) in-transit metastases;(3) T4 lesion;(4) perineural invasion;and (5) recurrent CSCC with at least one other risk factor. Patients with CSCC involvement in at least three lymph nodes (feature 1b) were added to the eligibility criteria, as this group was found to be at similar risk of CSCC recurrence as the initially planned study population. Protocol amendment now allows patients with chronic lymphocytic leukemia (CLL) who are not on active treatment to be enrolled. The study has two parts. In Part 1 (blinded), patients are randomly assigned 1:1 to receive cemiplimab 350 mg or placebo intravenously every 3 weeks for 12 weeks, followed by cemiplimab 700 mg or placebo every 6 weeks for 36 weeks. In optional Part 2 (unblinded), patients in the placebo arm who experience disease recurrence and patients in the cemiplimab arm who experience disease recurrence ≥3 months after completion of 48-week treatment in Part 1 are eligible to receive open-label cemiplimab 350 mg Q3W for up to 96 weeks. The trial is expected to enroll 412 patients from about 100 sites in North and South America, Europe, and Asia-Pacific regions. Key primary objective is to compare disease-free survival;secondary objectives include evaluating overall survival, freedom from locoregional relapse, and distant relapse with adjuvant cemiplimab versus placebo in patients with high-risk CSCC. This study is once again open for enrolment following interruptions owing to the COVID-19 pandemic. Not applicable (trial in progress) Not applicable (trial in progress) [ FROM AUTHOR] Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

2.
Journal of Clinical Oncology ; 40(16), 2022.
Article in English | EMBASE | ID: covidwho-2009660

ABSTRACT

Background: CSCC is the second most common skin cancer with an estimated incidence of 1 million cases per year in the US. While the surgical cure rate for CSCC is > 95%, some pts have high risk of recurrence as assessed by immune status, primary disease stage, extent of nodal involvement, presence of extracapsular extension (ECE), and prior treatment. Postoperative RT is recommended for these pts but relapse with locoregional recurrence or distant metastases may still occur. C-POST is evaluating the efficacy of cemiplimab as adjuvant therapy for pts with high-risk CSCC. Here, we provide summary of the most recent study protocol amendment. Methods: C-POST is a randomized, placebo-controlled, double-blind, multicenter Phase 3 study to evaluate cemiplimab as adjuvant treatment for pts with high-risk CSCC, based on surgical and clinicopathologic findings, who completed surgery and postoperative RT (minimum total dose 50Gy, within 10 weeks before randomization) (NCT03969004). Pts with at least one of the following high-risk features are eligible: (1) nodal disease with (a) ECE and at least one node ≥20 mm or (b) at least three lymph nodes positive on surgical pathology report, regardless of ECE;(2) in-transit metastases;(3) T4 lesion;(4) perineural invasion;and (5) recurrent CSCC with at least one other risk factor. Pts with CSCC involvement in at least three lymph nodes (feature 1b) were added to the eligibility criteria, as this group was found to be at similar risk of CSCC recurrence as the initially planned study population. Protocol amendment now allows patients with chronic lymphocytic leukemia (CLL) who are not on active treatment to be enrolled. The study has two parts. In Part 1 (blinded), pts are randomly assigned 1:1 to receive cemiplimab 350 mg or placebo intravenously every 3 weeks for 12 weeks, followed by cemiplimab 700 mg or placebo every 6 weeks for 36 weeks. In optional Part 2 (unblinded), pts in the placebo arm who experience disease recurrence and pts in the cemiplimab arm who experience disease recurrence ≥3 months after completion of 48-week treatment in Part 1 are eligible to receive open-label cemiplimab for up to 96 weeks. The trial is expected to enrol 412 pts from about 100 sites in North and South America, Europe, and Asia-Pacific regions. Key primary objective is to compare disease-free survival;secondary objectives include evaluating overall survival, freedom from locoregional relapse, and distant relapse with adjuvant cemiplimab versus placebo in patients with high-risk CSCC. This study is once again open for enrolment following interruptions owing to the COVID-19 pandemic.

3.
CARD Agricultural Policy Review ; 2021.
Article in English | CAB Abstracts | ID: covidwho-1871712

ABSTRACT

It is reported that the USDA outlook for US agriculture in 2021 is generally positive. Most agricultural markets, including the major markets for Iowa, have recovered from the depths of the price declines that struck during the early days of the COVID-19 pandemic. Some of the basic statistics (such as production, exports, imports, and prices) for cattle/beef, pigs/pigmeat, maize and soyabeans are presented.

4.
Journal of Social and Personal Relationships ; 39(1):92-99, 2022.
Article in English | Web of Science | ID: covidwho-1582709
6.
Sci Total Environ ; 816: 151534, 2022 Apr 10.
Article in English | MEDLINE | ID: covidwho-1510284

ABSTRACT

Wastewater monitoring of SARS-CoV-2 presents a means of tracking COVID-19 community infection dynamics on a broader geographic scale. However, accounting for environmental and sample-processing losses may be necessary for wastewater measurements to readily inform our understanding of infection prevalence. Here, we present measurements of the SARS-CoV-2 N1 and N2 gene targets from weekly wastewater samples at three sites in Hamilton County, Ohio, during an increase and subsequent decline of COVID-19 infections. The concentration of N1 or N2 RNA in wastewater, measured over the course of six months, ranged from below the detection limit to over 104 gene copies/l, and correlated with case data at two wastewater treatment plants, but not at a sub-sewershed-level sampling site. We also evaluated the utility of a broader range of variables than has been reported consistently in previous work, in improving correlations of SARS-CoV-2 concentrations with case data. These include a spiked matrix recovery control (OC43), flow-normalization, and assessment of fecal loading using endogenous fecal markers (HF183, PMMoV, crAssphage). We found that adjusting for recovery, flow, and fecal indicators increased these correlations for samples from a larger sewershed (serving ~488,000 people) with greater industrial and stormwater inputs, but raw N1/N2 concentrations corresponded better with case data at a smaller, residential-oriented sewershed. Our results indicate that the optimal adjustment factors for correlating wastewater and clinical case data moving forward may not be generalizable to all sewersheds.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Prevalence , RNA , Waste Water
7.
CARD Agricultural Policy Review ; : 11, 2020.
Article in English | CAB Abstracts | ID: covidwho-1489667

ABSTRACT

This article discusses the gradual recovery of the US agricultural sector during the pandemic. The first impact of the pandemic lowered agricultural prices, forced significant shifts in supply chains, and disrupted markets. However, as the summer progressed, there was some recovery in prices, supply chains realigned with consumer demand, and the markets rebalanced to the new conditions under COVID-19. To explore the extent of recovery in the US agricultural sector, the author updated the previous comparison of USDA's meat, corn, and soybean projections. The previous comparison ran from January 2020 (before the first confirmed case of COVID-19 in the United States) to USDA's June outlook. This update incorporates the changes from the most recent outlook, released in mid-October 2020, and reflects not only the impact of COVID-19, but also the progress on the US/China phase one trade deal and the natural disasters that struck the Midwest (drought and derecho). This article presents data that showed that while the initial impacts from COVID-19 struck nearly all US agricultural markets at the same time, the recoveries from that shock vary heavily and are still ongoing. For most of the meats and corn, the recovery thus far is partial-meats have seen better production, but lower prices, and corn has experienced lower production, but better prices, mostly due to factors other than COVID-19. Soybeans are the only commodity where we could argue the recovery is complete, as production and prices exceed pre-COVID-19 forecasts. However, 2020 is still a very challenging year in agriculture, but not quite as challenging as first envisioned.

8.
Online Learning ; 25(1):41-69, 2021.
Article in English | Web of Science | ID: covidwho-1155037

ABSTRACT

Like all educational institutions, community colleges rapidly shifted to online instruction in the wake of the COVID-19 pandemic. However, little is known about what factors shaped individual college responses. This survey of distance education leaders (N = 45) in the California community colleges system aimed to: (a) characterize pre-COVID distance education resources, emergency responses to the pandemic, and readiness for online instruction in the fall, and (b) determine how pre-COVID distance education resources, emergency responses, and fall readiness relate to each other. We find wide variability in pre-COVID distance education resources. These preexisting resources were related to institutions' responses: Colleges with fewer pre-COVID resources focused on foundational efforts such as creating online student services, while institutions with greater pre-COVID resources offered somewhat broader responses to training students and faculty in skills to successfully transition online. Finally, although colleges improved their readiness for continued remote instruction in the fall term in terms of training faculty and providing students with technology to access classes, respondents estimated that roughly a third of students would still face barriers accessing remote classes.

9.
The Medical journal / US Army Medical Center of Excellence ; - (PB 8-21-01/02/03):37-49, 2021.
Article in English | MEDLINE | ID: covidwho-1117837

ABSTRACT

SARS-CoV-2 has highlighted the requirement for a drastic change in pandemic response. While cases continue to rise, there is an urgent need to deploy sensitive and rapid testing in order to identify potential outbreaks before there is an opportunity for further community spread. Currently, reverse transcription quantitative polymerase chain reaction (RT-qPCR) is considered the gold standard for diagnosing an active infection, using a nasopharyngeal swab;however, it can take days after symptoms develop to properly identify and trace the infection. While many civilian jobs can be performed remotely, the Department of Defense (DOD) is by nature a very fluid organization which requires in-person interaction and a physical presence to maintain effectiveness. In this commentary, we examine several current and emergent technologies and their ability to identify both active and previous SARS-CoV-2 infection, possibly in those without symptoms. Further, we will explore an ongoing study at the Air Force Research Laboratory, utilizing Reverse Transcription Loop-mediated isothermal amplification (RT-LAMP), next-generation sequencing, and the presence of SARS-CoV-2 antibodies through Lateral Flow Immunoassays. The ability to identify SARS-CoV-2 through volatile organic compound biomarker identification will also be explored. By exploring and validating multiple testing strategies, and contributing to Operation Warp Speed, the DOD is postured to respond to SARS-CoV-2, and future pandemics.

10.
Agribusiness ; 37(1):122-141, 2021.
Article in English | CAB Abstracts | ID: covidwho-1086254

ABSTRACT

The novel coronavirus SARS-CoV2 (COVID-19) severely disrupted the U.S. food supply chain. In its initial aftermath, and as we contemplate a potential reignition, the food supply chain industries, researchers, and policy makers search for evidence, causes, and consequences. This article uses publicly available data on the pork and egg industries and a survey of the turkey industry as a first step to document the impact of COVID-19. Researchers can learn from the experiences in industries where disruptions evolve differently in the face of simultaneous supply- and demand-side shocks and that stem from differences in structures of the supply chains. This early evidence is used to motivate future research needs and highlight opportunities for industry investments in resiliency strategies.

11.
CARD Agricultural Policy Review ; : 4-5, 2020.
Article in English | CAB Abstracts | ID: covidwho-831149

ABSTRACT

Just like other sectors of the economy, the US agricultural sector has seen an economic downturn due to the COVID-19 pandemic. As various economic sectors resume activity, businesses are adjusting to living with the virus. Agricultural producers and USDA are reevaluating commodity markets and changing outlooks for the rest of the year. Schulz and Hart compare USDA's meat, corn, and soybean projections from January 2020 with the most recent update, released in mid-June 2020, and find that the outlook changes are much more concentrated on prices than production.

SELECTION OF CITATIONS
SEARCH DETAIL